Ergomed PLC (AIM:ERGO, ETR:2EM) (Ergomed PLC (AIM:ERGO, ETR:2EM), Ergomed PLC (AIM:ERGO, ETR:2EM)) Miroslav Reljanović, Egomed’s executive chairman talks to Proactive London's Katie Pilbeam about the acquisition of pharmaceutical quality assurance specialist ADAMAS for £25.6mln cash.
ADAMAS is focused on areas such as Good Clinical Practice (GCP), Good Pharmacovigilance Practice (GVP), Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP) and Computer Systems Compliance (CSC) (together, GxP) and has already worked with 40 of the world’s 50 largest pharma groups.
In 2021, revenues rose by 31% to £8.5mln with underlying profits of £1.8mln and ErgoMed said ADAMAS, which will continue to operate independently, would give an immediate boost to earnings.